Syncom Formulations (India) Ltd (SYNCOMF)
6.05
Syncom Formulations (India) Ltd Performance
| Returns % | |
| 1 Month Return | -12.03 % |
| 3 Month Return | -24.03 % |
| 1 Year Return | -48.82 % |
Syncom Formulations (India) Ltd Valuation
Syncom Formulations (India) Ltd in the last 5 years
Lowest (3.98x)
March 12, 2020
Today (27.86x)
March 20, 2023
Highest (81.74x)
January 18, 2022
27.86x
Price to Earnings TTM Ratio
Insights on Syncom Formulations India Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 3 quarters, 54.38Cr → 59.36Cr (in ₹), with an average increase of 4.3% per quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, SYNCOMF has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 3.59Cr → 4.14Cr (in ₹), with an average increase of 13.3% per quarter
NO EFFECTAgainst Peers
In the last 1 year, Dr Reddys Laboratories Ltd has given 9.7% return, outperforming this stock by 55.2%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 50.57% of holdings in Dec 2022 quarter
- NO EFFECT
Retail Holding Unchanged
Retail Investor holdings remained unchanged at 49.43% of holdings in Dec 2022 quarter
NEGATIVE IMPACTPrice Dip
In the last 6 months, SYNCOMF stock has moved down by -31.3%
Syncom Formulations (India) Ltd Peer Comparison
Syncom Formulations (India) Ltd Shareholding Pattern
| Investors | Holdings % | Prev. 4 periods | 3M change |
|---|---|---|---|
| Promoter Holdings | 50.57% | 0.00 | |
| Foreign Institutions | 0% | 0.00 | |
| Mutual Funds | 0% | 0.00 | |
| Retail Investors | 49.43% | 0.00 | |
| Others | 0% | 0.00 |
Syncom Formulations (India) Ltd Company Financials
Corporate Announcements
Syncom Formulations (India) Ltd Earnings Results
Syncom Formulations (India) Ltd’s net profit jumped 3.24% since last year same period to ₹4.14Cr in the Q3 2022-2023. On a quarterly growth basis, Syncom Formulations (India) Ltd has generated 15.32% jump in its net profits since last 3-months.
Read MoreSyncom Formulations (India) Ltd Dividends August,2022
In the quarter ending September 2022, Syncom Formulations (India) Ltd has declared dividend of ₹0.03 - translating a dividend yield of 0.5%.
Read More
Syncom Formulations (India) Ltd Company Information
Syncom Formulations (India) Ltd Share Price: ₹6.05 per share as on 22 Mar, 2023 04:01 PM
Syncom Formulations (India) Ltd Market Capitalisation: ₹705.00Cr as of today
Syncom Formulations (India) Ltd Revenue: ₹59.36Cr as on December 2022 (Q4 22)
Syncom Formulations (India) Ltd Net Profit: ₹4.14Cr as on December 2022 (Q4 22)
Syncom Formulations (India) Ltd Listing date: 11 Mar, 1994
Syncom Formulations (India) Ltd Chairperson Name: Kedarmal Bankda
| Organisation | Syncom Formulations (India) Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Frequently Asked Questions
Syncom Formulations (India) Ltd(SYNCOMF) share price today is ₹6.05 (last updated 22 Mar, 2023 at 04:01 PM)
- Today’s highest price of Syncom Formulations (India) Ltd(SYNCOMF) is ₹6.30.
- Today’s lowest price of Syncom Formulations (India) Ltd(SYNCOMF) is ₹5.95.
- (last updated 22 Mar, 2023 at 04:01 PM)
| Syncom Formulations (India) Ltd(SYNCOMF) | Price |
|---|---|
| 52 Week High | ₹11.60 |
| 52 Week Low | ₹5.80 |
| Syncom Formulations (India) Ltd(SYNCOMF) | Returns (%) |
|---|---|
| 1 Day Returns | 0.00% |
| 1 Month Returns | -12.03% |
| 1 Year Returns | -48.82% |
| 3 Year Returns | 891.53% |
| 5 Year Returns | 383.47% |
Indian stocks brokerage services are provided by INDmoney Private Limited. INDmoney Private Limited is carrying out the business of in respect to stock broking activities and also carries out the activities of depository participant. SEBI Registration No. INZ000305337 | SEBI Depository Participant Registration No. IN-DP-690-2022 Depository Participant ID: CDSL 12095500 | Trading and Clearing Member of NSE (90267, M70042) and BSE (6779)
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. The securities quoted are exemplary and not recommendatory. Past performance is not indicative of future returns.